- Home
- LXEH vs KLRS Comparison
LXEH vs KLRS Comparison
Compare LXEH & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- KLRS
- Stock Information
- Founded
- LXEH 2001
- KLRS 2019
- Country
- LXEH China
- KLRS United States
- Employees
- LXEH N/A
- KLRS N/A
- Industry
- LXEH Other Consumer Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LXEH Real Estate
- KLRS Health Care
- Exchange
- LXEH Nasdaq
- KLRS Nasdaq
- Market Cap
- LXEH 55.2M
- KLRS 46.0M
- IPO Year
- LXEH 2020
- KLRS N/A
- Fundamental
- Price
- LXEH $2.43
- KLRS $4.44
- Analyst Decision
- LXEH
- KLRS Strong Buy
- Analyst Count
- LXEH 0
- KLRS 2
- Target Price
- LXEH N/A
- KLRS $23.00
- AVG Volume (30 Days)
- LXEH 4.3M
- KLRS 726.0K
- Earning Date
- LXEH 09-26-2025
- KLRS 11-15-2025
- Dividend Yield
- LXEH N/A
- KLRS N/A
- EPS Growth
- LXEH N/A
- KLRS N/A
- EPS
- LXEH N/A
- KLRS N/A
- Revenue
- LXEH $4,493,795.00
- KLRS N/A
- Revenue This Year
- LXEH N/A
- KLRS N/A
- Revenue Next Year
- LXEH N/A
- KLRS N/A
- P/E Ratio
- LXEH N/A
- KLRS N/A
- Revenue Growth
- LXEH N/A
- KLRS N/A
- 52 Week Low
- LXEH $1.12
- KLRS $2.14
- 52 Week High
- LXEH $50.08
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- LXEH 63.64
- KLRS 59.74
- Support Level
- LXEH $2.26
- KLRS $3.49
- Resistance Level
- LXEH $2.69
- KLRS $4.90
- Average True Range (ATR)
- LXEH 0.22
- KLRS 0.81
- MACD
- LXEH 0.04
- KLRS 0.01
- Stochastic Oscillator
- LXEH 73.20
- KLRS 32.54
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.